Michael J. Kukla

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives

Rudi Pauwels, Koen Andries, Jan Desmyter et al. · Nature · 1990 · 757 citations

Medicine, Medicinal Chemistry, Pharmacology +12

Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-nucleoside Reverse Transcriptase Inhibitors That Are Highly Potent and Effective against Wild-Type and Drug-Resistant HIV-1 Variants

Kalyan Das, Arthur D. Clark, Paul Lewi et al. · Journal of Medicinal Chemistry · 2004 · 511 citations

Life Sciences, Medicinal Chemistry, Pharmacology +17

TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1

Koen Andries, Hilde Azijn, Theo Thielemans et al. · Antimicrobial Agents and Chemotherapy · 2004 · 322 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +17

Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues

Donald Ludovici, Bart L. De Corte, Michael J. Kukla et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 185 citations

Pharmacy, Medicinal Chemistry, Pharmacology +12

An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives.

Zeger Debyser, Rudi Pauwels, Koen Andries et al. · Proceedings of the National Academy of Sciences · 1991 · 167 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16